Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 107.61 percent decrease over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $2.02 million which missed the analyst consensus estimate of $2.31 million by 12.43 percent. This is a 43.90 percent decrease over sales of $3.60 million the same period last year.